Comparing Durvalumab, Olaparib, and Cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior Bevacizumab: the phase II NRG-GY023 trial 2025

ARRY-382 in combination with pembrolizumab in patients with advanced solid tumors: results from a phase 1b/2 study 2022